JM173

JM173 is a peptide-based antagonist of the C-X-C chemokine receptor type 4 (CXCR4), derived from the endogenous human peptide EPI-X4 (Endogenous Peptide Inhibitor of CXCR4). It is an optimized derivative designed to improve the binding affinity and stability of the parent peptide. CXCR4 is a G protein-coupled receptor that plays a significant role in various pathological processes, including tumor cell migration, hematopoiesis, and inflammation. In the context of metastatic breast carcinoma, JM173 is used to target cancer cells and osteoclasts that overexpress CXCR4. It has been studied as a component of supramolecular delivery systems, such as the (JM173)3-Avi-C3 biohybrid, where it acts as both a therapeutic inhibitor of CXCR4 signaling and a targeting ligand to deliver cytotoxic or inhibitory cargoes (like the Rho-inhibitor C3bot) directly to the cytosol of target cells. This dual approach is intended to disrupt the vicious cycle of bone metastasis by inhibiting cancer cell proliferation and reducing osteoclast-mediated bone resorption.

Other names

EPI-X4 derivative JM173EPI-X-4 derivative JM173EPI-X 4 derivative JM173EPI-X4 JM173EPI-X-4 JM173EPI-X 4 JM173